ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014

Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Yuni K Dewaraja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.